HUTCHMED: regulatory filings accepted for review for ORPATHYS plus TAGRISSO in MET-driven EGFR-mutated lung cancer in Europe and Japan

HUTCHMED announced that regulatory filings for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) in MET-driven EGFR-mutated lung cancer have been accepted for review in Europe and Japan.

Detected & updated continuously · Source: Nebula